Mylan now offers generic alternatives to Truvada®,
Atripla® and Viread® to patients in
Canada1
HERTFORDSHIRE, England and
PITTSBURGH and TORONTO, Aug. 10,
2017 /PRNewswire/ -- Mylan Pharmaceuticals ULC, a subsidiary
of Mylan N.V. (NASDAQ, TASE: MYL), a leading global pharmaceutical
company, today announced the launch in Canada of three generic products indicated in
the treatment of HIV for certain patients. One of the products is
Mylan-Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg, a
generic alternative to Truvada®.
Mylan received final approval from Health Canada for this
product and for Mylan-Efavirenz/Emtricitabine/Tenofovir Disoproxil
Fumarate 600 mg, 200 mg, and 300 mg, a generic alternative to
Atripla®; and Mylan-Tenofovir Disoproxil 300 mg, a generic
alternative to Viread®.
Mylan's Chief Commercial Officer Tony
Mauro said, "Mylan has a strong and sustained commitment to
expanding access to treatment for HIV/AIDS and other diseases
around the world, and today marks another milestone in those
efforts. More than 40% of people worldwide being treated for
HIV/AIDS with an antiretroviral depend on a Mylan product every
day, and we're proud to further expand access to such medicines in
Canada."
Approximately 37 million people globally are living with
HIV/AIDS today. As a champion for access, Mylan has invested
$250 million in expanding its
antiretroviral (ARV) production capacity, enabling the company to
produce 4 billion ARV tablets and capsules every year.
Mylan-Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg
is indicated in combination with other antiretroviral agents for
the treatment of HIV-1 infection in adults.
Mylan-Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate 600
mg, 200 mg, and 300 mg is indicated for use alone as a complete
regimen or in combination with other antiretroviral agents for the
treatment of HIV-1 infection in adults.
Mylan-Tenofovir Disoproxil 300 mg is indicated for the treatment
of HIV-1 infection in combination with other antiretroviral agents
in patients 12 years of age and older and the treatment of chronic
hepatitis B infection in adults.
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 7,500 marketed products around the world,
including antiretroviral therapies on which approximately 50% of
people being treated for HIV/AIDS in the developing world depend.
We market our products in more than 165 countries and territories.
We are one of the world's largest producers of active
pharmaceutical ingredients. Every member of our more than
35,000-strong workforce is dedicated to creating better health for
a better world, one person at a time. Learn more at Mylan.com or
Mylan.ca.
1 Truvada® and Viread® are registered trademarks of
Gilead Sciences, Inc. or its related companies. Atripla® is a
registered trademark of Bristol-Myers Squibb & Gilead Sciences,
LLC.
View original content with
multimedia:http://www.prnewswire.com/news-releases/mylan-advances-access-in-the-fight-against-hiv-with-the-launch-of-three-generic-antiretroviral-medicines-in-canada-300502284.html
SOURCE Mylan N.V.